John P. Neoptolemos
YOU?
Author Swipe
View article: Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study Open
View article: Estimating treatment effects using parametric models as counter-factual evidence
Estimating treatment effects using parametric models as counter-factual evidence Open
View article: Therapie des Pankreaskarzinoms: Innovative Chirurgie und moderne Systemtherapien
Therapie des Pankreaskarzinoms: Innovative Chirurgie und moderne Systemtherapien Open
View article: GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial
GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial Open
Background: No prognostic biomarker is currently used in clinical management of patients with surgically resected pancreatic cancer other than CA-19-9. In this study, we tested the prognostic value of GATA6 measured with immunohistochemist…
View article: Characterization of single neurons reprogrammed by pancreatic cancer
Characterization of single neurons reprogrammed by pancreatic cancer Open
View article: Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial Open
PURPOSE The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survi…
View article: Tumour plasticity and tumour microenvironment interactions as potential immunologic targets for pancreatic cancer treatment
Tumour plasticity and tumour microenvironment interactions as potential immunologic targets for pancreatic cancer treatment Open
Pancreatic ductal adenocarcinoma (PDAC) is a malignant cancer with a high mortality and limited treatment options. Systemic chemotherapy remains the only approach for improving survival in patients with unresectable locally advanced and/or…
View article: Polymorphisms within autophagy‐related genes as susceptibility biomarkers for pancreatic cancer: A meta‐analysis of three large European cohorts and functional characterization
Polymorphisms within autophagy‐related genes as susceptibility biomarkers for pancreatic cancer: A meta‐analysis of three large European cohorts and functional characterization Open
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with patients having unresectable or metastatic disease at diagnosis, with poor prognosis and very short survival. Given that genetic variation within autophagy‐rela…
View article: Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response
Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response Open
View article: Therapie des Pankreaskarzinoms: Innovative Chirurgie und moderne Systemtherapien
Therapie des Pankreaskarzinoms: Innovative Chirurgie und moderne Systemtherapien Open
View article: A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma
A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma Open
Pleiotropic variants (i.e. genetic polymorphisms influencing more than one phenotype) are often associated with cancer risk. A scan of pleiotropic variants was successfully conducted 10 years ago in relation to pancreatic ductal adenocarci…
View article: ESMO 2023 pancreatic cancer guidelines signal stepwise progress
ESMO 2023 pancreatic cancer guidelines signal stepwise progress Open
View article: Interventions for Pancreatitis—New Approaches, Knowledge Gaps, and Research Opportunities
Interventions for Pancreatitis—New Approaches, Knowledge Gaps, and Research Opportunities Open
There exists no cure for acute, recurrent acute or chronic pancreatitis and treatments to date have been focused on managing symptoms. A recent workshop held by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) f…
View article: Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk
Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk Open
View article: Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: a meta-analysis of four large European cohorts and functional characterization
Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: a meta-analysis of four large European cohorts and functional characterization Open
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers. The vast majority of patients have unresectable or metastatic disease at diagnosis, with poor prognosis and very short survival. Considering this fact, it is urgent…
View article: Personalized treatment in localized pancreatic cancer
Personalized treatment in localized pancreatic cancer Open
View article: Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC Open
Neoadjuvant chemotherapy can improve the survival of individuals with borderline and unresectable pancreatic ductal adenocarcinoma; however, heterogeneous responses to chemotherapy remain a significant clinical challenge. Here, we performe…
View article: Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians
Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians Open
View article: Adjuvant Chemotherapy in Pancreatic Cancer
Adjuvant Chemotherapy in Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma is likely to become the second leading cause of cancer mortality within the next decade. There have been some improvements in diagnosis and treatments, but there is still much work to be done. This chapter …
View article: A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarcinoma
A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarcinoma Open
Coding sequence variants comprise a small fraction of the germline genetic variability of the human genome. However, they often cause deleterious change in protein function and are therefore associated with pathogenic phenotypes. To identi…
View article: Determination of “borderline resectable” pancreatic cancer – A global assessment of 30 shades of grey
Determination of “borderline resectable” pancreatic cancer – A global assessment of 30 shades of grey Open
Interobserver variability among radiologists and surgeons globally is high, calling into question the consistency of clinical decision making for patients with PDAC and suggesting that central review may be required for studies of neoadjuv…
View article: The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years’ experience of association studies to understand the genetic architecture of pancreatic cancer
The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years’ experience of association studies to understand the genetic architecture of pancreatic cancer Open
View article: Supplementary Table S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Table S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Patient Characteristics of iTRAQ sample pools.
View article: Supplementary Figure 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Supplementary Figure 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties Open
Fibroblast markers and RT-PCR validation for mRNA and microRNA arrays.
View article: Supplementary Table 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Supplementary Table 1 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties Open
Patient characteristics of samples used for discovery and independent validation.
View article: Supplementary Table 3 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Supplementary Table 3 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties Open
Patient characteristics of UoL serum sample cohorts.
View article: Supplementary Table S4. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Table S4. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
Comparison of TSP-1 serum levels in PDAC patients with clinicopathological parameters.
View article: Supplemental Methods from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Supplemental Methods from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties Open
Supplementary Material and Methods
View article: Supplementary Table 4 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties
Supplementary Table 4 from Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties Open
Patient characteristics of samples included on TMAs histologically stained for TNC.
View article: Supplementary Figure S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Supplementary Figure S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus Open
(A) Peptides unique to TSP-1 (in red) were used to quantify the protein using multiple reaction monitoring (MRM). (B) Detection of TSP-1 by western analysis in UKCTOCS and PBRU samples. Human Foreskin Fibroblast (HFF) cells treated with TS…